Arrivent Biopharma, INC. (AVBP) — SEC Filings

Q: What are the key financial highlights for Arrivent Biopharma, INC.?

Key financial highlights for Arrivent Biopharma, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Arrivent Biopharma, INC.?

Key executives at Arrivent Biopharma, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Arrivent Biopharma, INC. stock?

Risk factors for Arrivent Biopharma, INC. (AVBP) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Arrivent Biopharma, INC.?

Forward-looking statements and predictions from Arrivent Biopharma, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Arrivent Biopharma, INC.. Recent 10-Q filing on Nov 10, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Arrivent Biopharma, INC. on SEC EDGAR

Overview

Arrivent Biopharma, INC. (AVBP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: ArriVent BioPharma, Inc. (AVBP) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $130.8 million, up from $59.9 million for the same period in 2024. This 118% increase was primarily driven by a substantial rise in research and development (R&D) expens

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 1 bearish, 32 neutral, 2 mixed. The dominant filing sentiment for Arrivent Biopharma, INC. is neutral.

Filing Type Overview

Arrivent Biopharma, INC. (AVBP) has filed 6 10-Q, 14 8-K, 2 10-K, 8 SC 13G, 1 8-K/A, 1 SC 13D, 2 S-1/A, 1 S-1 with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (35)

ArriVent's R&D Surge Drives 118% Net Loss Increase to $130.8M — 10-Q · Nov 10, 2025 Risk: high
ArriVent BioPharma, Inc. (AVBP) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $130.8 million, up from $59.9
ArriVent BioPharma Files 8-K — 8-K · Sep 9, 2025 Risk: low
On September 9, 2025, ArriVent BioPharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial stateme
ArriVent's Losses Widen Amid R&D Surge, Bolstered by $172.5M Offering — 10-Q · Aug 11, 2025 Risk: medium
ArriVent BioPharma, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company experience
ArriVent BioPharma Files 8-K Report — 8-K · Jul 21, 2025 Risk: low
On July 21, 2025, ArriVent BioPharma, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specifi
ArriVent BioPharma Enters Material Definitive Agreement — 8-K · Jul 2, 2025 Risk: medium
On July 1, 2025, ArriVent BioPharma, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offic
ArriVent BioPharma Files 8-K — 8-K · Jun 23, 2025 Risk: low
ArriVent BioPharma, Inc. filed an 8-K on June 23, 2025, reporting on other events and financial statements. The filing does not contain specific financial figur
ArriVent BioPharma Files 8-K on Shareholder Vote Matters — 8-K · Jun 20, 2025 Risk: low
ArriVent BioPharma, Inc. filed an 8-K on June 20, 2025, reporting on matters submitted to a vote of security holders on June 18, 2025. The filing details the co
ArriVent BioPharma Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: low
ArriVent BioPharma, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key financial da
ArriVent BioPharma Elects New Directors, Discloses Officer Compensation — 8-K · Apr 28, 2025 Risk: low
On April 23, 2025, ArriVent BioPharma, Inc. announced the election of Dr. Jonathan Lim and Mr. David E. Johnson to its Board of Directors. The company also disc
ArriVent BioPharma Changes Auditors — 8-K · Mar 13, 2025 Risk: low
ArriVent BioPharma, Inc. announced on March 11, 2025, a change in its certifying accountant. The company has appointed PricewaterhouseCoopers LLP as its new ind
ArriVent BioPharma Files 2024 10-K — 10-K · Mar 3, 2025 Risk: medium
ArriVent BioPharma, Inc. filed its 2024 10-K on March 3, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, in
ArriVent BioPharma Enters Material Definitive Agreement — 8-K · Jan 22, 2025 Risk: medium
On January 21, 2025, ArriVent BioPharma, Inc. entered into a material definitive agreement. The company also disclosed information under Regulation FD and filed
SC 13G Filing — SC 13G · Dec 4, 2024
ArriVent BioPharma Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
ArriVent BioPharma, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third
SC 13G Filing — SC 13G · Nov 14, 2024
SC 13G Filing — SC 13G · Nov 12, 2024
SC 13G Filing — SC 13G · Nov 12, 2024
SC 13G Filing — SC 13G · Nov 8, 2024
SC 13G Filing — SC 13G · Oct 24, 2024
SC 13G Filing — SC 13G · Oct 11, 2024
ArriVent BioPharma Files 8-K Report — 8-K · Sep 9, 2024 Risk: low
On September 9, 2024, ArriVent BioPharma, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, with no s
ArriVent BioPharma Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
ArriVent BioPharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business ope
ArriVent BioPharma Files 8-K/A Amendment — 8-K/A · Jul 9, 2024 Risk: low
ArriVent BioPharma, Inc. filed an amendment (8-K/A) on July 9, 2024, to its report originally dated April 20, 2024. This amendment pertains to the departure of
ArriVent BioPharma Enters Material Definitive Agreement — 8-K · Jun 5, 2024 Risk: medium
On June 4, 2024, ArriVent BioPharma, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial Statemen
ArriVent BioPharma Appoints New CMOs — 8-K · May 16, 2024 Risk: low
On May 16, 2024, ArriVent BioPharma, Inc. announced the appointment of Dr. Jonathan F. Miller as Chief Medical Officer and Dr. Michael J. Zelefsky as Chief Medi
ArriVent BioPharma Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: low
ArriVent BioPharma, Inc. (AVBP) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. ArriVent BioPharma, Inc. filed a 10-Q report for the quarter ended
ArriVent Biopharma Appoints New CMO, Elects Director — 8-K · Apr 22, 2024 Risk: medium
ArriVent Biopharma, Inc. announced on April 20, 2024, the appointment of Dr. Jonathan F. Miller as Chief Medical Officer and the election of Ms. Sarah E. Kelly
ArriVent Biopharma Files 8-K on Financials — 8-K · Mar 28, 2024 Risk: low
On March 28, 2024, ArriVent Biopharma, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
ArriVent Biopharma, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: low
ArriVent Biopharma, Inc. (AVBP) filed a Annual Report (10-K) with the SEC on March 28, 2024. ArriVent Biopharma, Inc. filed its annual report on Form 10-K for t
SC 13G Filing — SC 13G · Feb 13, 2024
OrbiMed Discloses Active Stake in ArriVent Biopharma — SC 13D · Feb 5, 2024
OrbiMed Advisors LLC, along with its affiliated entities OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P., and OrbiMed Advisors IV Limited, filed an SC 13D
ArriVent Biopharma Files 8-K for Bylaw Amendments, Other Events — 8-K · Jan 30, 2024
ArriVent Biopharma, Inc. filed an 8-K on January 30, 2024, to report an amendment to its Articles of Incorporation or Bylaws, along with other events and financ
ArriVent Biopharma Files Amendment No. 2 to S-1 Registration Statement — S-1/A · Jan 23, 2024 Risk: low
ArriVent Biopharma, Inc. (AVBP) filed a Amended IPO Registration (S-1/A) with the SEC on January 23, 2024. ArriVent Biopharma, Inc. filed an amendment (No. 2) t
ArriVent Biopharma Files Amendment to S-1 Registration Statement — S-1/A · Jan 22, 2024 Risk: low
ArriVent Biopharma, Inc. (AVBP) filed a Amended IPO Registration (S-1/A) with the SEC on January 22, 2024. ArriVent Biopharma, Inc. filed an amendment (S-1/A) t
ArriVent Biopharma Files S-1 Registration Statement — S-1 · Jan 5, 2024 Risk: low
ArriVent Biopharma, Inc. (AVBP) filed a IPO Registration (S-1) with the SEC on January 5, 2024. ArriVent Biopharma, Inc. has filed an S-1 registration statement

Risk Profile

Risk Assessment: Of AVBP's 25 recent filings, 1 were flagged as high-risk, 8 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Arrivent Biopharma, INC.'s most recent 10-Q filing (Nov 10, 2025):

Revenue: $0
Net Income: -$130.8M
EPS: -$3.54
Debt-to-Equity: 0.07
Cash Position: $305.4M
Operating Margin: N/A
Total Assets: $326.6M
Total Debt: $21.6M

Key Executives

Dr. Jonathan Lim
Mr. David E. Johnson
Dr. Jonathan F. Miller
Dr. Michael J. Zelefsky
Ms. Sarah E. Kelly
Zhengbin (Bing) Yao, Ph.D.
John T. Rudy

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like ArriVent BioPharma operate in a competitive landscape where success is heavily dependent on the efficacy and safety of drug candidates, clinical trial outcomes, and eventual market approval. The industry relies heavily on external financing to fund these capital-intensive operations.

Top Tags

financials (5) · 8-k (4) · 10-Q (4) · biopharma (4) · ArriVent Biopharma (4) · sec-filing (3) · material-definitive-agreement (3) · corporate-governance (3) · IPO (3) · Registration Statement (3)

Key Numbers

Net Loss: $130.8M — for the nine months ended September 30, 2025, up from $59.9M in 2024
Research and Development Expenses: $121.2M — for the nine months ended September 30, 2025, up from $58.8M in 2024
Accumulated Deficit: $369.1M — as of September 30, 2025
Cash, Cash Equivalents, and Marketable Securities: $305.4M — as of September 30, 2025, deemed sufficient for 12 months of operations
Net Cash Provided by Financing Activities: $168.3M — for the nine months ended September 30, 2025
Net Cash Used in Operating Activities: $129.9M — for the nine months ended September 30, 2025
Outstanding Shares of Common Stock: 41,281,361 — as of November 7, 2025
Net Loss Per Share: $0.83 — for the three months ended September 30, 2025, compared to $0.61 in 2024
Commission File Number: 001-41929 — Identifier for the company's SEC filings
IRS Employer Identification No.: 86-3336099 — Company's tax identification number
Revenue: $0 — No revenue reported for Q2 2025, consistent with clinical-stage operations.
Net Loss (Q2 2025): $38.5M — Increased from $28.1M in Q2 2024, reflecting higher R&D expenses.
Net Loss (YTD Q2 2025): $73.2M — Increased from $52.9M in YTD Q2 2024, driven by R&D investments.
R&D Expenses (Q2 2025): $32.1M — Up from $22.7M in Q2 2024, primarily due to furmonertinib clinical trials.
Gross Proceeds from Public Offering: $172.5M — Raised on July 3, 2025, significantly bolstering cash reserves post-quarter.

Frequently Asked Questions

What are the latest SEC filings for Arrivent Biopharma, INC. (AVBP)?

Arrivent Biopharma, INC. has 35 recent SEC filings from Jan 2024 to Nov 2025, including 14 8-K, 8 SC 13G, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of AVBP filings?

Across 35 filings, the sentiment breakdown is: 1 bearish, 32 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Arrivent Biopharma, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Arrivent Biopharma, INC. (AVBP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Arrivent Biopharma, INC.?

Key financial highlights from Arrivent Biopharma, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for AVBP?

The investment thesis for AVBP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Arrivent Biopharma, INC.?

Key executives identified across Arrivent Biopharma, INC.'s filings include Dr. Jonathan Lim, Mr. David E. Johnson, Dr. Jonathan F. Miller, Dr. Michael J. Zelefsky, Ms. Sarah E. Kelly and 2 others.

What are the main risk factors for Arrivent Biopharma, INC. stock?

Of AVBP's 25 assessed filings, 1 were flagged high-risk, 8 medium-risk, and 16 low-risk.

What are recent predictions and forward guidance from Arrivent Biopharma, INC.?

Forward guidance and predictions for Arrivent Biopharma, INC. are extracted from SEC filings as they are enriched.